- Home
- IMMX vs PAVS Comparison
IMMX vs PAVS Comparison
Compare IMMX & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- PAVS
- Stock Information
- Founded
- IMMX 2014
- PAVS 2004
- Country
- IMMX United States
- PAVS United States
- Employees
- IMMX N/A
- PAVS N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- IMMX Health Care
- PAVS Health Care
- Exchange
- IMMX Nasdaq
- PAVS Nasdaq
- Market Cap
- IMMX 82.6M
- PAVS 68.0M
- IPO Year
- IMMX 2021
- PAVS 2019
- Fundamental
- Price
- IMMX $3.05
- PAVS $0.58
- Analyst Decision
- IMMX Strong Buy
- PAVS
- Analyst Count
- IMMX 1
- PAVS 0
- Target Price
- IMMX $8.00
- PAVS N/A
- AVG Volume (30 Days)
- IMMX 453.7K
- PAVS 470.7K
- Earning Date
- IMMX 11-11-2025
- PAVS 08-04-2025
- Dividend Yield
- IMMX N/A
- PAVS N/A
- EPS Growth
- IMMX N/A
- PAVS N/A
- EPS
- IMMX N/A
- PAVS N/A
- Revenue
- IMMX N/A
- PAVS $71,542.00
- Revenue This Year
- IMMX N/A
- PAVS N/A
- Revenue Next Year
- IMMX N/A
- PAVS N/A
- P/E Ratio
- IMMX N/A
- PAVS N/A
- Revenue Growth
- IMMX N/A
- PAVS N/A
- 52 Week Low
- IMMX $1.34
- PAVS $0.46
- 52 Week High
- IMMX $3.20
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- IMMX 77.89
- PAVS 30.14
- Support Level
- IMMX $2.31
- PAVS $0.53
- Resistance Level
- IMMX $2.82
- PAVS $1.22
- Average True Range (ATR)
- IMMX 0.25
- PAVS 0.10
- MACD
- IMMX 0.08
- PAVS -0.06
- Stochastic Oscillator
- IMMX 95.41
- PAVS 15.56
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.